

**Summary of the Major Components of the  
California Stem Cell Research, Treatments, and Cures Initiative of 2020**

- Authorizes \$5.5 billion in state general obligation bonds to fund stem cell research, therapy development, and therapy delivery in California.
- Dedicates, subject to peer review recommendations and board approval, at least \$1.5 billion to fund stem cell research, therapy development, and therapy delivery focused on diseases and conditions of the brain, such as Alzheimer's disease, Parkinson's disease, stroke, dementia, epilepsy, depression, brain cancer, schizophrenia, autism, and other diseases and conditions of the brain.
- Expands Alpha Stem Cell Clinic Program and establishes Community Care Centers of Excellence at which clinical trials are conducted and treatments and cures are intended to be made available to California patients.
- Establishes training and fellowship programs, the goal of which is to ensure that California has the workforce necessary to move new discoveries from the research stage to the clinic, to accelerate the availability of treatments and cures, and to make treatments and cures arising from CIRM-funded research available to California patients, including preparing California undergraduates and master's students for technical careers in stem cell and related research.
- Re-establishes the Shared Research Labs Program to fund specialized instrumentation, a supply of cell lines, culture materials, and instruction and training in research methods and techniques at universities and non-profit research institutions in California.
- Establishes the Treatments and Cures Accessibility and Affordability Working Group. The Working Group is tasked with recommending policies to the Governing Board intended to increase access to human clinical trials and the availability and affordability of treatments and cures arising from CIRM-funded research.
- Establishes scientific advisory board comprising 10 members, 5 appointed by the Chair and 5 appointed by the President to advise on scientific and policy matters, including funding priorities, portfolio strategies, collaborations, and opportunities for matching funds.
- Expands Governing Board from 29 to 35 members to include representatives from UC Riverside and the UCSF Fresno/Clovis campuses, expand the number of patient advocates, and adds two nurses with experience in clinical trial management and therapy delivery.
- Requires revenue from intellectual property generated by CIRM-funded research be deposited in California's General Fund. To the extent permitted by law, such funds are required be used to offset the costs of providing treatments and cures arising from CIRM-funded research to California patients who have insufficient means to purchase the treatment or cure.
- Requires Governing Board of CIRM to develop conflict of interest standards, in consultation with the National Academy of Sciences and the Scientific and Medical Accountability Standards Working Group, for the consideration of funding awards based on best practices established by the National Academies of Sciences to prevent conflicts of interest in the award of research funding.
- Requires Governing Board to update standards, at least every four years, relating to conflicts of interest, ethical research and treatment, and independent financial audits.

- Imposes cap of 70 employees, plus up to 15 additional employees dedicated to supporting the development of policies and programs designed to help make treatments and cures arising from CIRM-funded research available and affordable for Californians.
- Allocates two percent of amount available for grants for facilities, equipment, and operations of Community Care Centers of Excellence (1.5%) and Shared Labs (0.5%).